Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
14th August 2020 | Earl W Brien | 150,000 | Exercise of derivative | $0.26 | $39,000.00 |
7th August 2020 | Steven A Kriegsman | 3,000,000 | Exercise of derivative | $0.26 | $780,000.00 |
7th August 2020 | Steven A Kriegsman | 1,164,179 | Payment by withholding | $0.67 | $779,999.93 |
7th August 2020 | Louis Ignarro | 700,000 | Exercise of derivative | $0.26 | $182,000.00 |
7th August 2020 | Louis Ignarro | 271,642 | Payment by withholding | $0.67 | $182,000.14 |
7th August 2020 | Joel K Caldwell | 450,000 | Exercise of derivative | $0.26 | $117,000.00 |
7th August 2020 | Joel K Caldwell | 174,627 | Payment by withholding | $0.67 | $117,000.09 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
CytRx Corp. is a biopharmaceutical research and development company. It focuses on developing novel anti-cancer drug candidates. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.